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1124-95 Reticulated Platelets in Acute Coronary Syndrome: A 
Potential Marker for Platelet Consumption 
V&xi Tsyboulev, J. Jorgenssen, Abdus Saleem, Nasser M. Lakkia Baylor College Of 
Medicine, Houston, TX 
Introduction: The physiologic sequalae of damage to the vascular endothelium which 
include platelet adhesion to subendothelial elements in the blood vessel wall, recruitment 
of circulating platelets to form a hemostatic plug, and its subsequent consolidation with 
fibrin strands are now well established. We hypothesize that the presence of circulating 
reticulated (containing-RNA) platelets is potentially a reliable marker for platelet aggrega- 
tlon and thrombus formation in acute coronary syndrome. 
Methods Forty-seven subjects (15 controls, 32 patients with acute coronary syndrome) 
were studied. All patients had chest pain within 24 hours along with lschemic ST changes 
on the ECG or evidence of myocardial injury. Blood was collected for platelet count, 
mean platelet volume, and for flow cytometric analysis for the presence of reticulated 
platelets as assessed by uptake thiazole orange, and the expression of CD4la for the 
GPllbillla receptor on the platelet membrane. All studies were repeated in the presence 
of RNA-ase with evidence of 90% decrease of thiazole orange uptake, 
Results The mean platelet count was 220+32 in the control group and 207*45 in the 
acute coronary syndrome patients. The mean platelet volume was statistically higher in 
pabents than in controls (IO&l fl vs. 9&0.5 fl. p=O.OOS). Sixteen percent of the overall 
platelet population was reticulated in the acute coronary syndrome group compared to 
only 3 percent in the control group. Patients admitted with ST-elevation acute coronary 
syndrome had more reticulated platelets than those with non- ST-elevation (21.3i6.9 vs. 
14.9*6.9, p=O.Ol). Also, diabetic patients presenting with acute coronary syndrome had 
a significantly higher percentage of circulating reticulated platelets compared to non dia- 
betic patients (p=O.O003). Aspinn seems to eliminate these differences. 
Conclusion: Reticulated platelets appear to be a reliable marker for platelet aggregation 
and consumption in acute coronary syndrome. More studies are needed to further under- 
stand this novel observation. 
1124-114 EARLY Platelet Substudy 
Paul A. Gurbel, Raymond D. Bahr, Matt T. Roe, Victor L. Serbruany, Alex I. Maknin, W. 
8. Gibler, E. M. Ohman, Sinai Center for Thrombosis Research, Baltimore, MD, Duke 
University Medical Center, Durham, NC 
Background: Receptors other than GP Ilb/llla may mediate leukocyte-platelet-endothe- 
lial interactions that obstruct the microvasculature in acute coronary syndromes (ACS) 
and cause microinfarcts. The effect of eptifibatide (EP) on these receptors was investi- 
gated in the EARLY trial. Methods: Platelet receptors (mean fluorescense intensity) and 
aggregation (1% mol ADP) were determined at baseline, and at 3,6,12 and 24 hours 
after randomization to early (E) ( ID the Emergency Department, n=27) or late (L) (12-24 
hours, n=28) EP therapy. ResuI1s: Aggregation was inhibited by early EP (baseline, 72 * 
20% ; 3 hours post, 7i 9 %p<O.OOl). CD31, CD63, CD 107a, CD 107b. CD 41 (GPllbillla 
expression), and CD 62p were not affected in either group. Leukocyte-platelet aggre- 
gates trended upward after presentation (early baseline, 43.1* 26.0 versus 65.8 k35.6, 
p= 09). PAC.1 (GPllbillla activity), CD 51/61 (vitronectin receptor and CD 42b (GP lb) 
were inhibited by EP (pc.05). Conclusion: In Emergency Dept patients with ACS, EP 
rapidly and profoundly inhibits platelet aggregation and reduces GP Ilb/llla activity and 
the expression of CD51/61 and CD 42b; the latter two effects may also contribute to the 
drug’s anti-thrombotic effect. However, platelet-leukocyte aggregate formation, a marker 
of platelet activity rises within 24 hours after presentation despite eptifibatide therapy and 
is a potential mechanism for microvascular obstruction. 
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1124-115 Eptifibatide Provides Additional Platelet Inhibition in 
Non-ST Elevation Myocardial Infarction Patients 
Already Treated With Aspirin and Clopidogrel: Results 
of the PEACE Study 
Miles C. Dalby, Gilles Montalescot, Claire Bal-dit-Sollier. Eric Vicaut. Jean-Phillipe Collet, 
Remi Choussat, Vanessa Gallois, Gerard Drobinski, Ludovic Drouet, Daniel Thomas, 
Pitie Salpetriere Hospital, Paris, France 
Background: Thienopyridines and glycoprotein(Gp) Ilb/llla antagonists have been 
tested separately with success in the treatment of non ST elevation myocardlal infarction 
(NSTEMI). Although often co-prescribed in this context, the antiplatelet interaction of 
these agents is poorly described and the superiority of Gpllblllla antagomsts above 
thienopyridine treatment alone is not clear. The hypothesis of the study was that eptifi- 
batide offered further antlplatelet effect above clopidogrel in the medical stabilisation of 
NSTEMI prior to expeditive PCI. 
Methods: 32 NSTEMI patients treated with aspirin and enoxaparin were studied using 
flow-cytometry to define parameters of platelet activation with a panel of agonists before 
clopidogrel, following clopidogrel and during an eptifibatide infuslon. 
Results: With ADP, TRAP and U46. relative reductions in PAC-1 expression (conforma- 
tionally activated Gp Ilb/llla receptor) of 51%, 46% and 39% (all p<O.OOOl) respectively 
were seen with clopldogrel but a further 85%, 84% and 72% (all pcO.0001) reduction was 
seen with eptifibatide. Fibrinogen binding was significantly reduced followng clopidogrel 
by 77%, 63% and 69% (all p<O.OOOl) and again further reduced by 99% 98% and 98% 
(all pcO.0001) with eptifibatide. The total number of Gpllb/llla receptors (P2) and P-selec- 
tin expression were also reduced followng clopidogrel, with all agonists, (~~0.026, ADP 
and TRAP) however both parameters increased slightly in all cases with eptifibatide 
(p<O.O12 with ADP). 
Conclusion: The actwated Ilb/llla expression and fibrinogen binding findings indicate 
that eptifibatide provides significant potent antiplatelet activity above that of clopidogrel 
suggesting additive immediate protection in the treatment of NSTEMI. The P2 and P- 
selectin findings suggest the possibility of a partial agonist (and/or pro-inflammatory) 
effect, the consequences of which, with longer infusions are unknown. 
1124-l 16 Predictors of Early Mortality From an Unselected 
Patient Registry of Acute Coronary Syndromes 
(TRACS) 
James E. Calvin, Jr., Peter Meyers, Anthony Joseph, Allan Jaffe, TRACS Investigators, 
Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL 
Background: Several stratification models exist to predict early and late complications 
from an acute coronary syndrome (ACS). Most of these models are based on patient 
populations selected from randomued clinical trials and most are used to predict com- 
posite outcomes. The goal of this study was to determine predictors of mortality as a sol- 
itary end point in an unselected cohort of patients presenting to the Emergency 
Department (ED) with an ACS. 
Methods: The Registry of Acute Coronary Syndromes (TRACS) represents a dataset of 
all patients presenting with an ACS to the ED of 9 parlicipating centers. 
Results: Three thousand four hundred sixty four patients of whom 60% were male and 
17% were minorities comprised the TRACS registry. Sixty two percent were admitted. 
The in-hospital mortality rate for admitted patients was 9%. Patients who died in-hospital 
were older (72 YS 67 y. p = < .OOl), more likely Caucasian (90% vs 82%, p= .013), and 
more likely to have an elevated troponin I (64% vs 46%, p= < ,001). Conventional risk 
factors were similar but non-survivors received beta-blockers (36% vs 44% p = < ,021). 
nitrates (27% vs 54% p < .OOl), Ilb/llla platelet blockers (4% vs 13%, p= q ,001) and IV 
nitrates in the ED (24% vs 44%, p < ,001) less often. Multivariate analysis revealed 
increased age (odds ratlo, 95 Cl’s; 1.02, 1 .Ol- 1.03; p c .OOl), and an elevated troponin 
(1.866, 1.32. 2.60; p <. 001) to be associated with Increased mortality while in-hospital 
Ilb/llla use (.28. .12- .65; p= ,003) and IV nitrate use in the ED (.44, .33-.59: p< ,001) 
were associated wth reduced mortality. 
Conclusion: In this unselected population of admitted acute coronary syndrome 
patients, mortality was associated wth age and elevated troponin levels while In-hospital 
use of llbillla platelet blockers and IV nitrate therapy were associated with hospital surv- 
vorship. These results reaffirm the prognoshc value of age and troponins and the value of 
more aggressive medical management. 
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1125-96 Performance of the Thrombolysis in Myocardial 
Infarction Risk Index for Early Acute Coronary 
Syndrome in the National Registry of Myocardial 
Infarction: A Simple Risk Index Predicts Mortality in 
Both ST and Non-ST Elevation Myocardial Infarction 
Stephen D. Wiviott, David A. Morrow, Robert P. Giugliano, Paul D. Frederick, Carolyn H. 
McCabe, Christopher P. Cannon, Elliott M. Antman, Eugene Braunwald, Brigham & 
Women’s Hospital, Boston, MA 
Background: A simple risk Index (heart rate x [Age/lO]?SBP) developed from patients 
with ST elevation myocardial Infarction (STEMI) accurately predicts mortality in clirwal 
trials of fibrinolysls, but has not been evaluated in a general population with STEMI or 
non-ST elevation Ml (NSTEMI). 
Methods: To evaluate the TIMI Risk Index (TRI) I” such a population in the US, we 
tested it in the National Registry of Myocardial Infarction (NRMI) 3 and 4. NRMI patients 
were divided into pre-defined risk groups based on the derivation set from patietns 
receiving fibrinolysls in InTIME Il. 
Results: 117,676 patients with STEMI and 238,815 with NSTEMI were eligible for analy- 
sis. NRMI STEMI patients had a higher risk profile than those in the derivation set 
(Median TRI: 27 vs. 20). Dlwsion of those with STEMI into 5 pre-defined risk groups 
